China News Service, Xi’an, November 8 (Yang Yingqi) A reporter learned from the First Affiliated Hospital of Xi’an Jiaotong University (hereinafter referred to as the First Affiliated Hospital of Xi’an Jiaotong University) on the 8th that the country’s first extracorporeal membrane oxygenation equipment (hereinafter referred to as ECMO) The First Affiliated Hospital of Xi'an Jiaotong University took the lead in clinical application in China and successfully treated two critically ill cardiovascular patients.

　　According to reports, a patient in the First Affiliated Hospital of Xi’an Jiaotong University was diagnosed with type A aortic dissection and was admitted to the hospital. After the operation, he developed severe hypoxemia due to inflammation. After mechanical ventilation, the oxygenation did not improve. After communicating with the patient’s family, the hospital VV-ECMO (venous to vein) treatment was performed on the patient, and the patient's blood oxygen gradually improved.

Another patient in the hospital had aortic valve insufficiency, ascending aortic aneurysm-like expansion, acute left heart failure, emergency surgery after admission, and postoperative heart failure. After communicating with the patient’s family, VA-ECMO was performed. ) Auxiliary cardiac therapy, the patient's condition is stable after operation.

After medical evaluation, the above two patients were successfully withdrawn from ECMO.

　　Since the emergence of the new coronary pneumonia epidemic in early 2020, ECMO has gradually become known to the public as it is a powerful "weapon" for the treatment of patients with severe cardiopulmonary failure.

However, its core key technology has been monopolized by foreign countries for a long time, and the equipment and consumables are expensive.

　　It is reported that the first domestic ECMO was jointly developed by the First Affiliated Hospital of Xi'an Jiaotong University, the National Engineering Research Center for Biomedical Materials of Sichuan University, and the School of Mechanical Engineering of Xi'an Jiaotong University.

Before the outbreak of the new crown epidemic in 2020, the R&D team has basically completed sample trial production of ECMO centrifugal pump equipment and a full range of consumables, and conducted large animal experiments on anticoagulation coatings.

　　It is understood that the R&D team fully analyzed and compared the advantages and disadvantages of similar foreign products and the problems in clinical use, and designed a localized ECMO for domestic clinical needs.

In the research and development, multi-objective optimization and numerical simulation methods are used to obtain the optimal design scheme for the flow channel of the centrifugal pump. The chip-based control mode is used to ensure the accuracy of ECMO control and the safety of long-term work. The product has a more excellent long-term circulating anticoagulant effect.

　　The First Affiliated Hospital of Xi’an Jiaotong University stated that the domestically-made ECMO was successfully applied in clinical practice, breaking the monopoly of foreign products in this field, achieving a breakthrough in the independent research and development of major domestic medical devices, and breaking the "card" for the treatment of critically ill patients with cardiovascular disease. The "neck" problem is another major scientific research achievement of the hospital in establishing the National Medical Center.

(over)